# First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Source: https://onco.cc/trials/nct06043817/  
OnCo record `nct06043817` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of STX-721/PFL-721 (Escalated) in non-small-cell lung cancer, run by Pierre Fabre Medicament, now recruiting.

## Summary

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations is a phase 1/2 interventional study registered as NCT06043817 by Pierre Fabre Medicament, with 345 participants planned, started 2023-09-26 and due to reach its primary completion in 2029-12-01. Interventions recorded: STX-721/PFL-721 (Escalated), STX-721/PFL-721 (3 dose levels) and STX-721/PFL-721 (RP2D).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06043817
- Phase: 1/2
- Setting: First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- Sponsor: Pierre Fabre Medicament
- Enrolled: 345

## Sources

- ClinicalTrials.gov NCT06043817: https://clinicaltrials.gov/study/NCT06043817

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct06043817.json